NovoCure
NVCR
66 hedge funds and large institutions have $228M invested in NovoCure in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 10 closing their positions.
291% more call options, than puts
Call options by funds: $2.31M | Put options by funds: $591K
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
16% more capital invested
Capital invested by funds: $196M → $228M (+$31.9M)
14% more funds holding
Funds holding: 58 → 66 (+8)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.2M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$9.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.25M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.63M |
| 2 |
Alkeon Capital Management
New York
|
-$2.85M |
| 3 |
Morgan Stanley
New York
|
-$2.82M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.64M |
| 5 |
RCM
Riverhead Capital Management
Wilmington,
Delaware
|
-$661K |
NVCR Hedge Fund Activity: Q2 2016 in Review
66 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2016, worth a combined $228M — up 16% from $196M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NVCR positions and 10 closed out — a net gain of 9 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $29.2M. The largest seller was Fidelity Investments, cutting an estimated $6.63M.
- 66 institutional investors held NovoCure (NVCR) as of Q2 2016, up from 58 in Q1 2016.
- Funds reported $228M of NovoCure stock for Q2 2016, up 16% quarter-over-quarter.
- 19 funds opened new NovoCure positions in Q2 2016 and 10 closed out, a net change of +9 holders.
- The largest NovoCure buyer in Q2 2016 was Vanguard Group, an estimated $29.2M added.
- The largest NovoCure seller in Q2 2016 was Fidelity Investments, an estimated $6.63M sold.
Based on aggregated 13F filings for Q2 2016.